0
Editorial |

Considering Competing Risks . . . Not All Black and White

Jane A. Cauley, DrPH; Kristine E. Ensrud, MD, MPH
Arch Intern Med. 2008;168(8):793-795. doi:10.1001/archinte.168.8.793.
Text Size: A A A
Published online

Extract

Osteoporosis and type 2 diabetes mellitus (DM), 2 of the most common chronic conditions, represent major public health burdens. The lifetime risk of an osteoporotic fracture ranges from 40% to 50% in women and from 13% to 22% in men.1,2 The goal of osteoporosis treatment is to reduce fractures because fractures cause significant morbidity and mortality. Diabetes mellitus affects 7% of the US population, or 20.8 million people.3 The goal of glucose-lowering treatment is to reduce long-term microvascular and macrovascular complications of the disease. Pharmacologic options for the treatment of osteoporosis and type 2 DM have expanded exponentially during the past decade.4,5 Trials in osteoporosis have demonstrated a reduction in risk of fracture with pharmacologic treatment. Trials in type 2 DM have demonstrated improvement in glycemic control with treatment. However, most trials have not been designed to determine the effect of treatment on risk of macrovascular outcomes (myocardial infarction and stroke). The decision to treat an individual patient with a given medication for a specific condition should be made with consideration of the risks associated with no treatment and of the benefits, risks, and adverse effects of each therapy.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 6

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Osteoporosis

Users' Guides to the Medical Literature
A trial of sodium fluoride as secondary prevention against osteoporosis in postmenopausal women...

brightcove.createExperiences();